April 28th, 2020 – BitCare Technologies Inc. (BitCare), a Dallas, TX-based Biotech startup, has been working on various solutions to combat the COVID-19 pandemic with the recent launch of RT-PCR Lab tests and Rapid IgM/IgG Antibody Tests and has been working on potential solutions for therapeutic drugs for COVID-19.
“It has been one of the most challenging times of our lifetime; we at BitCare and our partners have been working on several solutions to fight the Coronavirus outbreak.” Ric S. Kolluri, CEO of BitCare, adds, “I’m thrilled to see that the computer models have shown great success in our findings for a potential Therapeutic Drug to fight the COVID-19.”
Since the onset of the COVID-19 infections is relatively recent, drugs have not been engineered to combat the illness. BitCare has been working with its research and development (R&D) partner Lynxbioscience LLC (Lynxbio), a Dallas, TX-based biopharma company and contract research organization (CRO) that provides drug discovery, drug development, and drug lifecycle management services. Hence, all efforts at BitCare and Lynxbio are directed to “repurpose” existing FDA approved drugs to find the appropriate prescription or cocktail that can help cure SARS-CoV-2 infections.
Dr. Siva Yadavalli, Chief Scientist of BitCare and CEO of Lynxbio, says, “Using the help of AI-based computer-aided models, we have identified potential drugs that are repurposed against protease targets encoded by the SARS-CoV-2 genome. These drugs belong to diverse therapeutic areas such as antiviral, antibacterial agents and have shown clinical evidence for treating respiratory disease in humans previously. Also,our team is working on novel therapeutic uses of Fullerenes and Fullerene derivatives for their potential applications in mitigating SARS-CoV-2.”
Our R&D partner Lynxbio has conducted virtual screening from their highest potential and clinically evidence-based 35 FDA approved drugs from their library, and found five lead molecules that have the potential to bind proteases of SARS-CoV-2 with high affinity. Jags Porandla, COO of Bitcare, says, “This discovery is not only innovative but also revolutionary that can help in flattening the curve of the novel coronavirus cases around the world.”
Lynxbio plans to make the findings openly available to experimental biologists and biomedical researchers, to investigate the findings in experimental setups, and for the clinicians to evaluate the potential of these findings for anti-COVID-19 treatment. Dr. Siva Yadavalli says, “The team is further conducting final validations in collaboration with academic researchers and hopeful that our computational findings with further validation will provide a cost-and-time-effective framework for rapid treatment trials towards an effective COVID-19 therapy.” BitCare & Lynxbio, through its partnership, decided to file a utility patent on these discovered potential Therapeutic Drugs.
BitCare Technologies, Inc. is a Dallas, Texas-based Biotech startup offering COVID-19 (RT-PCR Lab and Rapid IgM/IgG Antibody test and PPE) services and AI-based precision health and wellness services through at-home DNA & Allergy testing. DNA products offer personalized insights based on a person’s DNA on Health, Diet, Exercise, Sport, Estrogen, Addiction, Behavior, and also provides some advanced DNA tests in Parkinson’s, Alzheimer’s, ALS, and Dementia. All tests are simple to use at-home tests with a simple 20-second cheek swab; with free shipping. Also, BitCare offers Allergy, Intolerance, and Sensitivity testing, which analyzes up to 800 food and non-food items. All the tests are accessible through a secure BitCare’s platform.
Lynxbioscience LLC is a Dallas, Texas-based bio-pharmaceuticals and outsourcing company (Contract Research Organization-CRO), conducts research in drug development with “OMICS” technologies. Lynxbioscience has leading scientific experts, state-of-the-art technologies as well as critical therapeutic expertise in the areas of neuroscience, oncology, diabetes, pain, inflammation, infectious diseases, respiratory diseases, fibrosis, and rare diseases. Lynxbioscience is the first biotech company in the Texas region that offers comprehensive next-generation omics technologies services for novel and repurposed drug research to diversified groups such as pharmaceuticals, academic, and biotechnology clients. Lynxbioscience intends leveraging the expertise, comprehensive knowledge-based infrastructure in multi-disciplinary therapeutic areas in a systematic and unbiased manner with “OMICS” technologies.